Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences
Rhea-AI Summary
Beam Therapeutics (Nasdaq: BEAM) announced that its management will take part in fireside chats at three investor conferences in September 2026: Wells Fargo 21st Annual Healthcare Conference on September 8 in Boston, Citi’s Biopharma Back to School Conference on September 9 in New York, and Cantor Fitzgerald Global Healthcare Conference 2026 on September 10 in New York. Live webcasts and 60-day archives will be available in the investor section of Beam’s website.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 04 | Second-quarter earnings | Neutral | +9.4% | Quarterly loss and pipeline milestones accompanied the earnings release. |
| Jul 23 | Clinical data presentation | Positive | -2.7% | Updated BEAM-302 data were scheduled for a late-breaking ERS presentation. |
| Jun 18 | IND clearance | Positive | +5.1% | The FDA cleared BEAM-304's investigational new drug application for PKU. |
| May 18 | Clinical data presentation | Positive | -1.8% | Beam presented updated BEAM-302 Phase 1/2 data at the ATS conference. |
| May 13 | Nonprofit sponsorship | Positive | +0.8% | Beam became an inaugural industry sponsor supporting Alpha-1 detection. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Historical reactions were mixed, with positive moves following the August 4 earnings report and June 18 FDA clearance but declines after two clinical-data announcements.
Key Terms
base editing technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences:
- Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, 2026 at 1:30 p.m. ET in Boston
- Citi’s Biopharma Back to School Conference on Wednesday, September 9, 2026 at 1:00 p.m. ET in New York
- Cantor Fitzgerald Global Healthcare Conference 2026 on Thursday, September 10, 2026 at 8:00 a.m. ET in New York
The live webcasts will be available in the investor section of the company's website at www.beamtx.com and will be archived for 60 days following the presentation.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Contact:
Holly Manning
Beam Therapeutics
hmanning@beamtx.com
